Capital raising, board renewal and management changes
Open PDF
| Stock | The Hydration Pharmaceuticals Company Ltd (HPC.ASX) |
|---|---|
| Release Time | 15 Jun 2026, 9:35 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Hydration Pharmaceuticals Announces Capital Raising and Leadership Changes
Key Points
- Firm commitment to raise A$392k via placement
- Appointment of two new Non-Executive Directors
- CEO resignation with consultancy services to ensure smooth transition
Full Summary
The Hydration Pharmaceuticals Company Ltd (ASX: HPC) announced a capital raising initiative to issue 98 million new shares at $0.004 each, aiming to raise A$392k. Funds will support sales momentum in the US and working capital. The company also plans to issue 49 million options at $0.006 per option, subject to shareholder approval. Additionally, the company has appointed two new Non-Executive Directors and will reduce Board remuneration by 50%. The CEO, Oliver Baker, will resign but continue as a consultant. Emily Lease will take over as General Manager.
Guidance
Capital raising of A$392k expected to complete by 17 June 2026
Outlook
Expected improvement in operating cashflow performance from 3QFY26, with ongoing exploration of strategic M&A opportunities.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In